Videos & Articles
AGN NeuroScience and AGN Pharmaceuticals Media
Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI
How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment
Disseminated on Behalf of: Algernon Pharmaceuticals Algernon sold its Ifenprodil research program in Q2 of this year to...
The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic...
Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon...
Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s...
SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
“Drug Could Possibly Both Reduce Acute Damage of the Stroke” - How DMT Could be the Future of Stroke Treatment...
Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough
CEO Christopher J. Moreau provides an update on the Company's Ifendprodil drug program targeting chronic cough. The Company...
Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update
Algernon Pharmaceuticals CEO Christopher J. Moreau provides update on AP-188 DMT (Dimethyltryptamine) Stroke Program....
Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Canadian clinical-stage psychedelics company Algernon PharmaceuticalsAGNPF’s newly created subsidiary Algernon NeuroScience...
Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds
On January 17th, the company Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announced that they had dosed the first...
Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has...
The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil
In the video interview above, and article which follows, Algernon Pharmaceuticals CEO Christopher J. Moreau shares that the...
Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company has...
Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Algernon Forms Private Subsidiary To Advance Psychedelic Stroke Program Canadian clinical-stage psychedelics biotech...
Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has decided...
Wonderland 2022 Recap: Algernon Pharmaceuticals
With Wonderland still fresh in our rear-view mirrors, let’s take a moment to look at some of the highlights from the big...
The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF)
I first was introduced to Algernon roughly a year ago. When I was, the lead “theme” seemed to be that the company...
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (AGNPF) has begun screening subjects for its...
MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke
Christopher Moreau, CEO and Director of Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF)...
Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals Mr. Moreau is the CEO of Algernon...
Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies
The Canadian company Algernon (CSE:AGN; Frankfurt:AGW0; OTCQB:AGNPF) is the headline sponsor for the Wonderland psychedelic...
© Algernon NeuroScience – All Rights Reserved 2023 Privacy Policy